Trial · NCT07881926
Evaluation of MD60002 Device for Facial Skin Aging
NCT07881926, Not applicable, Not yet recruiting, Promoitalia Group Spa
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of MD60002 Device for Facial Skin Aging. Trials, record NCT07881926. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881926
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of MD60002 Device for Facial Skin Aging
- NCT number
- NCT07881926
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 43 participants, estimated
- Lead sponsor
- Promoitalia Group Spa
- Conditions
- Facial Wrinkles, Skin Aging, Skin Imperfections
- Interventions
- Device: MD60002
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from Baseline in Lemperle Wrinkle Assessment Scale (LWSS) Score | Baseline (Day 0) and 30 (± 7) days after the final treatment visit | Change in wrinkle severity evaluated using the Lemperle Wrinkle Assessment Scale (LWSS). The scale ranges from 0 (no wrinkles) to 5 (very deep wrinkles, redundant fold). A lower score indicates greater aesthetic improvement. |
| Primary | Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs) and Device Defect Logs | From baseline (Day 0) up to 30 (± 7) days post-treatment | Assessment of device safety evaluated through the recording, incidence, severity, and causal relationship of local and systemic adverse events, local injection site reactions (e.g., erythema, edema, pain), and device defects throughout the study duration. |
| Primary | Investigator Global Aesthetic Improvement Scale (GAIS) Rating | 30 (± 7) days after the final treatment visit | Assessment of overall aesthetic improvement rated by the Investigator using the GAIS 5-point scale (1 = Very Much Improved, 2 = Much Improved, 3 = Improved, 4 = No Change, 5 = Worse). |
| Secondary | Subject Satisfaction Score Measured by Global Aesthetic Improvement Scale (GAIS) | 30 (± 7) days after the final treatment visit (Visit 4) | Subject-assessed aesthetic improvement using the Global Aesthetic Improvement Scale (GAIS), a 5-point ordinal scale (1 = Very Much Improved, 2 = Much Improved, 3 = Improved, 4 = No Change, 5 = Worse). Success is defined as at least 70% of subjects reporting a score of 3 or lower. |
| Secondary | Incidence and Severity of Adverse Events (AEs) and Device Deficiencies | From baseline (Day 0) through 30 (± 7) days post-treatment follow-up | Incidence, frequency, and severity of treatment-emergent adverse events (AEs), serious adverse events (SAEs), device-related adverse effects (ADEs/SADEs), and device deficiencies recorded throughout the study. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 37705328 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881926
GET https://conductscience.org/api/trials/v1/NCT07881926/registered